The agency was appointed following a competitive pitch. It is Napp's first PR support for the inhaler in the UK.
Weber Shandwick currently handles the European PR account for the treatment.
The unnamed inhaler, which is a combined steroid and long-acting beta-agonist, is currently undergoing regulatory review and has yet to be approved for use in the UK.
Cambridge-based Napp has traditionally been known as a leader in pain management, but has started to branch out into other areas including respiratory and oncology. The PR programme will be led by Tonic Life senior account manger Sarah Schapira, with MD Neil Flash providing senior strategic support. The Tonic team will report to Napp group brand manager Sarah Ingle.
‘We will be advising on strategy and undertaking the tactical execution of activities across the communications spectrum, including both public relations and medical education,' said Flash. ‘This opportunity further strengthens Tonic's existing partnership with Napp, which extends to other areas of its expanding portfolio.'
Last year, Napp brought in Racepoint Group's associate director Rachel Cummings as health policy and advocacy manager.
The pharma firm also recently grabbed fifth position in The Sunday Times' Top 100 Companies to Work for 2010, and remains the highest ranked pharmaceutical company in the UK in this list.